Key Insights

Highlights

Treatment Research

2 treatments under study, led by Brentuximab Vedotin

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04795869Phase 2Withdrawn

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Showing all 1 trials

Research Network

Common Treatments

  • Brentuximab Vedotin1
  • Pembrolizumab1

Active Sponsors

  • Merck Sharp & Dohme LLC1
  • National Cancer Institute (NCI)1
  • Northwestern University1
  • Seagen Inc.1

Top Investigators

Related Conditions

  • Recurrent Angioimmunoblastic Tcell Lymphoma1
  • Recurrent Nodal Peripheral Tcell Lymphoma With Tfh Phenotype1
  • Recurrent Subcutaneous Panniculitislike Tcell Lymphoma1
  • Refractory Enteropathyassociated Tcell Lymphoma1
  • Refractory Nodal Peripheral Tcell Lymphoma With Tfh Phenotype1

Activity Timeline